Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-26-031922
Filing Date
2026-07-02
Accepted
2026-07-02 16:30:32
Documents
17
Period of Report
2026-07-02

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14a.htm   iXBRL DEF 14A 641438
2 GRAPHIC proxy_001.jpg GRAPHIC 536775
3 GRAPHIC proxy_002.jpg GRAPHIC 284726
  Complete submission text file 0001493152-26-031922.txt   3353166

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gtbp-20251231.xsd EX-101.SCH 7205
5 XBRL DEFINITION FILE gtbp-20251231_def.xml EX-101.DEF 10051
6 XBRL LABEL FILE gtbp-20251231_lab.xml EX-101.LAB 71208
7 XBRL PRESENTATION FILE gtbp-20251231_pre.xml EX-101.PRE 46764
20 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 90485
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40023 | Film No.: 261151882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)